Boardroom Alpha
Start trial
8-K primary document
JBTM · Current Report (Form 8-K) · Filed February 18, 2026

Jbt Marel Corp — 8-K exhibit

q42025segmentresultsrecast.htm
Jbt Marel Corp on Boardroom Alpha
Document

QUARTERLY BUSINESS SEGMENT INFORMATION
(Unaudited, and in millions)
Three months ended March 31, 2025Protein SolutionsPrepared Food and Beverage SolutionsTotal
Revenue$377.7$476.4
Less:
   Cost of sales247.3314.3
   Research and development19.79.5
   Other segment items (1)
76.6101.1
Add:
    Depreciation and amortization28.426.6
Segment Adjusted EBITDA (2)
$62.5$78.1$140.6 
Less:
Interest (income)(1.4)
Interest expense42.4
Other (income)(2.0)
Pension expense, other than service cost146.8
Restructuring related costs10.6
M&A related costs74.4
Depreciation and amortization60.6
Unallocated amounts:
Corporate expense (3)
28.4
Income (loss) from continuing operations before income taxes$(219.2)
(1) Other segment items for each reportable segment include operating expenses, which primarily consist of selling, general and administrative expenses and corporate and shared service expenses allocated to each segment based upon benefits received. Other segment items exclude the impact of restructuring, M&A and other one-time related costs as they do not reflect the ongoing operations of the underlying business.
(2) Total segment Adjusted EBITDA excludes unallocated corporate expenses and therefore is not equivalent to consolidated total Adjusted EBITDA, which was previously disclosed in JBT Marel's Q1 2025 financial results furnished with the Company's Form 8-K filed on May 5, 2025.
(3) Corporate expense is primarily comprised of unallocated selling, general and administrative expenses and activity that does not meet the criteria of a reportable segment. Corporate expense excludes the impact of depreciation and amortization, restructuring, M&A and other one-time related and non-operating costs shown separately in the table above.


QUARTERLY BUSINESS SEGMENT INFORMATION
(Unaudited, and in millions)
Three months ended June 30, 2025Protein SolutionsPrepared Food and Beverage SolutionsTotal
Revenue$421.5 $513.3 
Less:
Cost of sales270.1330.5
Research and development20.69.7
Other segment items (1)
88.0111.5
Add:
Depreciation and amortization43.431.9
Segment Adjusted EBITDA (2)
$86.2 $93.5 $179.7 
Less:
Interest (income)(2.8)
Interest expense31.8
Other (income)(3.0)
Loss on investment10.6
Pension expense, other than service cost0.2
Restructuring related costs5.6
M&A related costs20.0
Depreciation and amortization82.5
Unallocated amounts:
Corporate expense (3)
23.5
Income from continuing operations before income taxes$11.6 
(1) Other segment items for each reportable segment include operating expenses, which primarily consist of selling, general and administrative expenses and corporate and shared service expenses allocated to each segment based upon benefits received. Other segment items exclude the impact of restructuring, M&A and other one-time related costs as they do not reflect the ongoing operations of the underlying business.
(2) Total segment Adjusted EBITDA excludes unallocated corporate expenses and therefore is not equivalent to consolidated total Adjusted EBITDA, which was previously disclosed in JBT Marel's Q2 2025 financial results furnished with the Company's Form 8-K filed on August 5, 2025.
(3) Corporate expense is primarily comprised of unallocated selling, general and administrative expenses and activity that does not meet the criteria of a reportable segment. Corporate expense excludes the impact of depreciation and amortization, restructuring, M&A and other one-time related and non-operating costs shown separately in the table above.


QUARTERLY BUSINESS SEGMENT INFORMATION
(Unaudited, and in millions)
Three months ended September 30, 2025Protein SolutionsPrepared Food and Beverage SolutionsTotal
Revenue$440.8 $560.5 
Less:
   Cost of sales268.6372.9
   Research and development 21.69.1
   Other segment items (1)
72.6108.0
Add:
    Depreciation and amortization16.031.9
Segment Adjusted EBITDA (2)
$94.0 $102.4 $196.4 
Less:
Interest (income)(3.4)
Interest expense24.7
Other (income)(3.1)
Pension expense, other than service cost0.2
Restructuring related costs7.4
M&A related costs5.8
Depreciation and amortization55.4
Unallocated amounts:
Corporate expense (3)
25.5
Income from continuing operations before income taxes$83.7 
(1) Other segment items for each reportable segment include operating expenses, which primarily consist of selling, general and administrative expenses and corporate and shared service expenses allocated to each segment based upon benefits received. Other segment items exclude the impact of restructuring, M&A and other one-time related costs as they do not reflect the ongoing operations of the underlying business.
(2) Total segment Adjusted EBITDA excludes unallocated corporate expenses and therefore is not equivalent to consolidated total Adjusted EBITDA, which was previously disclosed in JBT Marel's Q3 2025 financial results furnished with the Company's Form 8-K filed on November 3, 2025.
(3) Corporate expense is primarily comprised of unallocated selling, general and administrative expenses and activity that does not meet the criteria of a reportable segment. Corporate expense excludes the impact of depreciation and amortization, restructuring, M&A and other one-time related and non-operating costs shown separately in the table above.


FY 2024 BUSINESS SEGMENT INFORMATION
(Unaudited, and in millions)
Twelve months ended December 31, 2024Protein SolutionsPrepared Food and Beverage SolutionsTotal
Revenue$168.7 $1,547.3 
Less:
Cost of sales92.0997.5
Research and development3.217.7
Other segment items (1)
29.6304.3
Add:
Depreciation and amortization13.673.4
Segment Adjusted EBITDA (2)
$57.5 $301.2 $358.7 
Less:
Interest (income)(23.7)
Interest expense19.4
Pension expense, other than service cost27.3
Restructuring related costs1.4
M&A related costs85.9
Depreciation and amortization89.4
Unallocated amounts:
Corporate expense (3)
63.6
Income from continuing operations before income taxes$95.4 
(1) Other segment items for each reportable segment include operating expenses, which primarily consist of selling, general and administrative expenses and corporate and shared service expenses allocated to each segment based upon benefits received. Other segment items exclude the impact of restructuring, M&A and other one-time related costs as they do not reflect the ongoing operations of the underlying business.
(2) Total segment Adjusted EBITDA excludes unallocated corporate expenses and therefore is not equivalent to consolidated total Adjusted EBITDA, which was previously disclosed in JBT Marel's full year 2024 financial results furnished with the Company's Form 8-K filed on February 24, 2025.
(3) Corporate expense is primarily comprised of unallocated selling, general and administrative expenses and activity that does not meet the criteria of a reportable segment. Corporate expense excludes the impact of depreciation and amortization, restructuring, M&A and other one-time related and non-operating costs shown separately in the table above.





FY 2023 BUSINESS SEGMENT INFORMATION
(Unaudited, and in millions)
Twelve months ended December 31, 2023Protein SolutionsPrepared Food and Beverage SolutionsTotal
Revenue$187.8 $1,476.6 
Less:
Cost of sales108.5970.2
Research and development4.915.7
Other segment items (1)
30.6287.2
Add:
Depreciation and amortization13.974.0
Segment Adjusted EBITDA (2)
$57.7 $277.5 $335.2 
Less:
Interest (income)(13.4)
Interest expense24.3
Pension expense, other than service cost0.7
Restructuring related costs11.4
M&A related costs6.0
Depreciation and amortization91.3
Unallocated amounts:
Corporate expense (3)
61.8
Income from continuing operations before income taxes$153.1 
(1) Other segment items for each reportable segment include operating expenses, which primarily consist of selling, general and administrative expenses and corporate and shared service expenses allocated to each segment based upon benefits received. Other segment items exclude the impact of restructuring, M&A and other one-time related costs as they do not reflect the ongoing operations of the underlying business.
(2) Total segment Adjusted EBITDA excludes unallocated corporate expenses and therefore is not equivalent to consolidated total Adjusted EBITDA, which was previously disclosed in JBT Marel's full year 2023 financial results furnished with the Company's Form 8-K filed on February 20, 2024.
(3) Corporate expense is primarily comprised of unallocated selling, general and administrative expenses and activity that does not meet the criteria of a reportable segment. Corporate expense excludes the impact of depreciation and amortization, restructuring, M&A and other one-time related and non-operating costs shown separately in the table above.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer